A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia

Mark R. Litzow, Sandra Lee, John M. Bennett, Gordon W. Dewald, Robert E. Gallagher, Vibha Jain, Elisabeth M. Paietta, Janis Racevskis, Steven R. Rousey, Joseph J. Mazza, Martin S. Tallman

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

We designed a phase II trial of arsenic trioxide (AT) for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The dose administered was 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days. Of 11 patients eligible, eight had B-cell and three T-cell ALL and two were Philadelphia chromosome-positive. The median duration of therapy was 21 days (range 7-28). One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL.

Original languageEnglish (US)
Pages (from-to)1105-1108
Number of pages4
JournalHaematologica
Volume91
Issue number8
StatePublished - Aug 2006

Keywords

  • Acute lymphoblastic leukemia
  • Arsenic trioxide
  • Relapse

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia'. Together they form a unique fingerprint.

  • Cite this

    Litzow, M. R., Lee, S., Bennett, J. M., Dewald, G. W., Gallagher, R. E., Jain, V., Paietta, E. M., Racevskis, J., Rousey, S. R., Mazza, J. J., & Tallman, M. S. (2006). A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia. Haematologica, 91(8), 1105-1108.